These innovative treatments, Semaglutide , represent a remarkable advancement in addressing metabolic dysfunction and conceivably associated conditions . They are classified as GLP-1 receptor agonists , indicating they function to emulate the endogenous GLP-1 substance , stimulating glucose relea